Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 25 Researches
7.8
USERS' SCORE
Good
Based on 2 Reviews
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D3 (as Cholecalciferol) (from Lanolin)
50 mcg (2,000 IU)
250%
Top Medical Research Studies
8
Vitamin D may reduce prostate cancer mortality
We set out to understand how vitamin D signaling within prostate cancer tumors might impact patient outcomes, particularly the risk of developing lethal forms of the disease. In our exploration, we analyzed data from 404 men with primary prostate cancer over a long follow-up period, assessing specific gene expressions linked to vitamin D in their tumor tissues.
Our findings revealed a noteworthy trend: the activation of vitamin D signaling in tumors was associated with a lower chance of progressing to lethal prostate cancer. Specifically, men with higher scores indicating active vitamin D signaling had a significantly reduced risk of metastasis or prostate cancer-related death compared to those with lower scores.
Interestingly, this protective association appeared to be stronger in individuals with predicted higher levels of vitamin D in their blood and those who had a body mass index of 25 or higher. With our research providing a clearer picture of how vitamin D functions within tumors, we believe there’s a solid basis for considering vitamin D interventions as potential strategies to enhance survival outcomes for prostate cancer patients.
Our findings revealed a noteworthy trend: the activation of vitamin D signaling in tumors was associated with a lower chance of progressing to lethal prostate cancer. Specifically, men with higher scores indicating active vitamin D signaling had a significantly reduced risk of metastasis or prostate cancer-related death compared to those with lower scores.
Interestingly, this protective association appeared to be stronger in individuals with predicted higher levels of vitamin D in their blood and those who had a body mass index of 25 or higher. With our research providing a clearer picture of how vitamin D functions within tumors, we believe there’s a solid basis for considering vitamin D interventions as potential strategies to enhance survival outcomes for prostate cancer patients.
Read More
9
Vitamin D3 may prevent prostate cancer
We explored how vitamin D3, specifically the metabolite 1α,25(OH)D, influences the behavior of non-cancerous prostate cells derived from African American men. In our study, we treated the RC-77N/E cell line with vitamin D3 and observed significant changes in gene expression after just 24 hours.
Our analysis revealed that 1α,25(OH)D affected 1,601 genes, highlighting its potential to suppress pathways linked to prostate cancer progression and cell proliferation. This points to the ability of vitamin D3 to help maintain non-malignant cell characteristics.
Additionally, we identified two specific genes, Anillin and Epithelial Cell Transforming 2, which were significantly downregulated by vitamin D3 treatment and correlated with better overall survival in prostate cancer patients. This suggests that these genes could serve as valuable biomarkers for assessing the risk of disease in affected individuals.
Given these promising findings, we believe that 1α,25(OH)D not only plays a vital role in regulating prostate health but could also be used as part of a preventative strategy or as an adjunct therapy, particularly for African American men who are disproportionately affected by prostate cancer.
Our analysis revealed that 1α,25(OH)D affected 1,601 genes, highlighting its potential to suppress pathways linked to prostate cancer progression and cell proliferation. This points to the ability of vitamin D3 to help maintain non-malignant cell characteristics.
Additionally, we identified two specific genes, Anillin and Epithelial Cell Transforming 2, which were significantly downregulated by vitamin D3 treatment and correlated with better overall survival in prostate cancer patients. This suggests that these genes could serve as valuable biomarkers for assessing the risk of disease in affected individuals.
Given these promising findings, we believe that 1α,25(OH)D not only plays a vital role in regulating prostate health but could also be used as part of a preventative strategy or as an adjunct therapy, particularly for African American men who are disproportionately affected by prostate cancer.
Read More
8
We explored the connection between vitamin D levels and their effects on prostate cancer risk and survival. Utilizing data from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, we looked closer at nearly 1,000 prostate cancer cases and their corresponding controls, analyzing the role of vitamin D alongside other vitamins like E and A.
Our findings suggest an interesting duality: higher vitamin D levels may increase the risk of developing prostate cancer, yet they also appear to support better survival among those diagnosed with the disease. Importantly, we found no evidence of biases that could distort these associations, suggesting that the relationship we observed is quite valid.
This research provides a critical insight into how vitamin D might play a beneficial role in surviving prostate cancer, warranting further investigation through controlled trials. Thus, while more research is needed, our results open the door for considering vitamin D as a potential factor in improving outcomes for prostate cancer patients.
Our findings suggest an interesting duality: higher vitamin D levels may increase the risk of developing prostate cancer, yet they also appear to support better survival among those diagnosed with the disease. Importantly, we found no evidence of biases that could distort these associations, suggesting that the relationship we observed is quite valid.
This research provides a critical insight into how vitamin D might play a beneficial role in surviving prostate cancer, warranting further investigation through controlled trials. Thus, while more research is needed, our results open the door for considering vitamin D as a potential factor in improving outcomes for prostate cancer patients.
Read More
Most Useful Reviews
8.8
Increased energy
I've been taking this vitamin since my prostate cancer diagnosis on my doctor's recommendation. After nearly 3 months, I've noticed an increase in energy and mood, along with a significant decrease in fatigue. The overall quality of life is still being assessed, but there has been a notable improvement thus far.
Read More
8
Essential for health
This supplement is essential for those in Taiwan who struggle to get enough sunlight. With insufficient sunlight here, D3 supplementation is crucial. My doctor, treating my early stage prostate cancer, recommends 2000IU on a non-daily basis, while others with terminal cancer are advised 5000IU. D3 is vital for post-cancer health and can benefit healthy individuals too.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 25 Researches
7.8
- All Researches
9
This study sought to uncover how vitamin D can help overcome challenges faced in treating castration-resistant prostate cancer (CRPC). We evaluated the powerful effects of certain vitamin D analogs in combination with the standard chemotherapy drug docetaxel, which often sees diminished effectiveness due to cancer cells developing resistance.
Our findings indicate that a specific vitamin D analog, Xe4MeCF3, outperforms natural vitamin D in activating the vitamin D receptor, which plays a crucial role in regulating cell growth and health. Notably, we observed that this compound not only helps restore sensitivity to docetaxel in lab-grown cancer spheroids but also reduces tumor growth in models derived from CRPC patients showing resistance to treatments.
This suggests a promising new avenue for enhancing the effectiveness of existing treatments for prostate cancer, especially for those who have not responded well to current options. By targeting key signaling pathways in cancer cells, vitamin D analogs like Xe4MeCF3 could significantly improve patient outcomes in the fight against this challenging disease.
Our findings indicate that a specific vitamin D analog, Xe4MeCF3, outperforms natural vitamin D in activating the vitamin D receptor, which plays a crucial role in regulating cell growth and health. Notably, we observed that this compound not only helps restore sensitivity to docetaxel in lab-grown cancer spheroids but also reduces tumor growth in models derived from CRPC patients showing resistance to treatments.
This suggests a promising new avenue for enhancing the effectiveness of existing treatments for prostate cancer, especially for those who have not responded well to current options. By targeting key signaling pathways in cancer cells, vitamin D analogs like Xe4MeCF3 could significantly improve patient outcomes in the fight against this challenging disease.
Read More
9
Vitamin D3 may prevent prostate cancer
We explored how vitamin D3, specifically the metabolite 1α,25(OH)D, influences the behavior of non-cancerous prostate cells derived from African American men. In our study, we treated the RC-77N/E cell line with vitamin D3 and observed significant changes in gene expression after just 24 hours.
Our analysis revealed that 1α,25(OH)D affected 1,601 genes, highlighting its potential to suppress pathways linked to prostate cancer progression and cell proliferation. This points to the ability of vitamin D3 to help maintain non-malignant cell characteristics.
Additionally, we identified two specific genes, Anillin and Epithelial Cell Transforming 2, which were significantly downregulated by vitamin D3 treatment and correlated with better overall survival in prostate cancer patients. This suggests that these genes could serve as valuable biomarkers for assessing the risk of disease in affected individuals.
Given these promising findings, we believe that 1α,25(OH)D not only plays a vital role in regulating prostate health but could also be used as part of a preventative strategy or as an adjunct therapy, particularly for African American men who are disproportionately affected by prostate cancer.
Our analysis revealed that 1α,25(OH)D affected 1,601 genes, highlighting its potential to suppress pathways linked to prostate cancer progression and cell proliferation. This points to the ability of vitamin D3 to help maintain non-malignant cell characteristics.
Additionally, we identified two specific genes, Anillin and Epithelial Cell Transforming 2, which were significantly downregulated by vitamin D3 treatment and correlated with better overall survival in prostate cancer patients. This suggests that these genes could serve as valuable biomarkers for assessing the risk of disease in affected individuals.
Given these promising findings, we believe that 1α,25(OH)D not only plays a vital role in regulating prostate health but could also be used as part of a preventative strategy or as an adjunct therapy, particularly for African American men who are disproportionately affected by prostate cancer.
Read More
9
We explored how vitamin D3, specifically 1α,25-dihydroxyvitamin D (often called calcitriol), influences the effects of ginsenoside Rh2 on prostate cancer cells. The study focused on both androgen-dependent LNCaP and androgen-independent C4-2 cell lines to analyze if this combination could enhance cancer-fighting properties.
Through various assays, we measured cell viability, proliferation, and the expression of key proteins involved in cancer growth and death. Our findings revealed that when we combined just 10 nM of vitamin D3 with ginsenoside Rh2, there was a marked improvement in reducing cell viability, with some treatments achieving up to an 80% decrease.
Moreover, we noticed that this collaboration also better suppressed the androgen receptor, which plays a significant role in prostate cancer development, while boosting the pro-apoptotic effects of Rh2. This combination suggests that vitamin D3 can potentiate the anticancer potential of Rh2, potentially lowering the required doses of the active vitamin D and minimizing side effects.
Through various assays, we measured cell viability, proliferation, and the expression of key proteins involved in cancer growth and death. Our findings revealed that when we combined just 10 nM of vitamin D3 with ginsenoside Rh2, there was a marked improvement in reducing cell viability, with some treatments achieving up to an 80% decrease.
Moreover, we noticed that this collaboration also better suppressed the androgen receptor, which plays a significant role in prostate cancer development, while boosting the pro-apoptotic effects of Rh2. This combination suggests that vitamin D3 can potentiate the anticancer potential of Rh2, potentially lowering the required doses of the active vitamin D and minimizing side effects.
Read More
8
We aimed to understand the role of vitamin D in treating prostate cancer, a serious disease that affects many men worldwide. The study highlights the problematic nature of advanced prostate cancer treatments, as most patients can develop resistance to standard hormone and chemotherapy options.
Our research showed a clear connection between low levels of vitamin D and the severity of prostate cancer, as well as the reduced presence of its receptor in prostate cells. This prompted us to investigate the effects of a vitamin D analog specifically in a mouse model designed for prostate cancer.
We observed that using this vitamin D analog positively impacted the tumor microenvironment in these mice. Moreover, we found that combining this vitamin D treatment with a common chemotherapy drug, docetaxel, helped overcome resistance observed in primary prostate cancer spheroids and in patient-derived xenografts that were resistant to both docetaxel and androgen deprivation.
Thus, our findings indicate that vitamin D analogs could be a promising new strategy for tackling advanced prostate cancer, offering hope for improving treatment outcomes for patients facing this challenging disease.
Our research showed a clear connection between low levels of vitamin D and the severity of prostate cancer, as well as the reduced presence of its receptor in prostate cells. This prompted us to investigate the effects of a vitamin D analog specifically in a mouse model designed for prostate cancer.
We observed that using this vitamin D analog positively impacted the tumor microenvironment in these mice. Moreover, we found that combining this vitamin D treatment with a common chemotherapy drug, docetaxel, helped overcome resistance observed in primary prostate cancer spheroids and in patient-derived xenografts that were resistant to both docetaxel and androgen deprivation.
Thus, our findings indicate that vitamin D analogs could be a promising new strategy for tackling advanced prostate cancer, offering hope for improving treatment outcomes for patients facing this challenging disease.
Read More
8
We investigated how vitamin D, specifically in its liposomal form, impacts prostate cancer using the TRAMP-C1 tumor model. Our findings indicate that liposomal vitamin D (VD-LP) significantly enhances anticancer effects while minimizing toxicity, unlike standard vitamin D therapies.
By preparing VD-LP using a film-hydration method, we ensured it was stable and effectively encapsulated, which set the stage for its evaluation in various cancer cell lines, including those representing prostate cancer.
When tested, VD-LP not only delayed tumor growth but also showed improved survival rates, all without triggering harmful levels of calcium in the blood. This is a crucial finding, as hypercalcemia can limit the use of vitamin D in clinical settings.
Overall, the study suggests that liposomal encapsulation of vitamin D could be a promising avenue for enhancing treatment strategies against prostate cancer, providing considerable hope for safer therapeutic options.
By preparing VD-LP using a film-hydration method, we ensured it was stable and effectively encapsulated, which set the stage for its evaluation in various cancer cell lines, including those representing prostate cancer.
When tested, VD-LP not only delayed tumor growth but also showed improved survival rates, all without triggering harmful levels of calcium in the blood. This is a crucial finding, as hypercalcemia can limit the use of vitamin D in clinical settings.
Overall, the study suggests that liposomal encapsulation of vitamin D could be a promising avenue for enhancing treatment strategies against prostate cancer, providing considerable hope for safer therapeutic options.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Increased energy
I've been taking this vitamin since my prostate cancer diagnosis on my doctor's recommendation. After nearly 3 months, I've noticed an increase in energy and mood, along with a significant decrease in fatigue. The overall quality of life is still being assessed, but there has been a notable improvement thus far.
Read More
8
Essential for health
This supplement is essential for those in Taiwan who struggle to get enough sunlight. With insufficient sunlight here, D3 supplementation is crucial. My doctor, treating my early stage prostate cancer, recommends 2000IU on a non-daily basis, while others with terminal cancer are advised 5000IU. D3 is vital for post-cancer health and can benefit healthy individuals too.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Len-Tayon K, Metzger D, Laverny G. [New insights of vitamin D-based therapy for prostate cancer]. Med Sci (Paris). 2025;41:154. doi:10.1051/medsci/2025011
- Ezcurra-Hualde M, Zalba S, Bella Á, Arrizabalaga L, Risson A, et al. Liposomal encapsulation of cholecalciferol mitigates toxicity and delays tumor growth. Front Immunol. 2025;16:1529007. doi:10.3389/fimmu.2025.1529007
- Etiévant L, Gail MH, Albanes D. Disentangling discordant vitamin D associations with prostate cancer incidence and fatality in a large, nested case-control study. Int J Epidemiol. 2024;53. doi:10.1093/ije/dyae110
- Vaselkiv JB, Shui IM, Grob ST, Ericsson CI, Giovannucci I, et al. Intratumoral vitamin D signaling and lethal prostate cancer. Carcinogenesis. 2024;45:735. doi:10.1093/carcin/bgae055
- Len-Tayon K, Beraud C, Fauveau C, Belorusova AY, Chebaro Y, et al. A vitamin D-based strategy overcomes chemoresistance in prostate cancer. Br J Pharmacol. 2024;181:4279. doi:10.1111/bph.16492
- Shi J, Yin C, Wu J. Possible non-linear relation between prostate specific antigen and vitamin D: a machine learning study based on cross-section data. J Cancer. 2024;15:3625. doi:10.7150/jca.96052
- Peppone LJ, Kleckner AS, Fung C, Puzas JE, Reschke JE, et al. High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT. Cancer. 2024;130:2538. doi:10.1002/cncr.35275
- Cui F, Qiu Y, Xu W, Zou C, Fan Y. Association Between Pretreatment Blood 25-Hydroxyvitamin D Level and Survival Outcomes in Patients With Clinically Localized Prostate Cancer: An Updated Meta-Analysis. Nutr Cancer. 2024;76:395. doi:10.1080/01635581.2024.2328378
- Park J, Ryu GW, Lee H, Choi YD, Kim Y. Frailty of Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review. World J Mens Health. 2024;42:347. doi:10.5534/wjmh.220280
- Danahy L, Long C, Hofmann TJ, Tara Z, Mark J, et al. Dietary vitamin D is a novel modulator of tumor engraftment through regulation of GC protein abundance. Res Sq. 2024. doi:10.21203/rs.3.rs-3911213/v1
- Ezcurra-Hualde M, Zalba S, Bella Á, Arrizabalaga L, Risson A, et al. Liposomal encapsulation of cholecalciferol mitigates toxicity and delays tumor growth. Front Immunol. 2025;16:1529007. doi:10.3389/fimmu.2025.1529007
- Vaselkiv JB, Shui IM, Grob ST, Ericsson CI, Giovannucci I, et al. Intratumoral vitamin D signaling and lethal prostate cancer. Carcinogenesis. 2024;45:735. doi:10.1093/carcin/bgae055
- Johnson JR, Martini RN, Yuan YC, Woods-Burnham L, Walker M, et al. 1,25-Dihydroxyvitamin D Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line. Biology (Basel). 2024;13. doi:10.3390/biology13050346
- Siddappa M, Hussain S, Wani SA, White J, Tang H, et al. African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1A. Cancer Res Commun. 2023;3:621. doi:10.1158/2767-9764.CRC-22-0389
- Erzurumlu Y, Aydogdu E, Dogan HK, Catakli D, Muhammed MT, et al. 1,25(OH) D induced vitamin D receptor signaling negatively regulates endoplasmic reticulum-associated degradation (ERAD) and androgen receptor signaling in human prostate cancer cells. Cell Signal. 2023;103:110577. doi:10.1016/j.cellsig.2022.110577
- Zhang ZH, Liu MD, Yao K, Xu S, Yu DX, et al. Vitamin D deficiency aggravates growth and metastasis of prostate cancer through promoting EMT in two β-catenin-related mechanisms. J Nutr Biochem. 2023;111:109177. doi:10.1016/j.jnutbio.2022.109177
- Karlsson S, Diaz Cruz MA, Faresjö M, Khamou AP, Larsson D. Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D in LNCaP Cells. Anticancer Res. 2021;41:4733. doi:10.21873/anticanres.15288
- Ben-Eltriki M, Deb S, Shankar G, Meckling G, Hassona M, et al. Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer. Medicines (Basel). 2021;8. doi:10.3390/medicines8060028
- Campbell RA, Li J, Malone L, Levy DA. Correlative Analysis of Vitamin D and Omega-3 Fatty Acid Intake in Men on Active Surveillance for Prostate Cancer. Urology. 2021;155:110. doi:10.1016/j.urology.2021.04.050
- Wu CT, Huang YC, Chen WC, Chen MF. Effect of 1α,25-Dihydroxyvitamin D3 on the Radiation Response in Prostate Cancer: Association With IL-6 Signaling. Front Oncol. 2021;11:619365. doi:10.3389/fonc.2021.619365
- García-Olivares M, Romero-Córdoba S, Ortiz-Sánchez E, García-Becerra R, Segovia-Mendoza M, et al. Regulation of anti-tumorigenic pathways by the combinatory treatment of calcitriol and TGF-β in PC-3 and DU145 cells. J Steroid Biochem Mol Biol. 2021;209:105831. doi:10.1016/j.jsbmb.2021.105831
- Ben-Eltriki M, Deb S, Guns EST. 1α,25-Dihydroxyvitamin D synergistically enhances anticancer effects of ginsenoside Rh2 in human prostate cancer cells. J Steroid Biochem Mol Biol. 2021;209:105828. doi:10.1016/j.jsbmb.2021.105828
- Igarashi K, Yui Y, Watanabe K, Kumai J, Nishizawa Y, et al. Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells. BMC Cancer. 2020;20:802. doi:10.1186/s12885-020-07310-5
- Nair-Shalliker V, Bang A, Egger S, Clements M, Gardiner RA, et al. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. Sci Rep. 2020;10:7736. doi:10.1038/s41598-020-62182-w
- Lai GR, Lee YF, Yan SJ, Ting HJ. Active vitamin D induces gene-specific hypomethylation in prostate cancer cells developing vitamin D resistance. Am J Physiol Cell Physiol. 2020;318:C836. doi:10.1152/ajpcell.00522.2019
